{
    "clinical_study": {
        "@rank": "163105", 
        "acronym": "CMCBRAF", 
        "arm_group": {
            "arm_group_label": "Mutated Anti-B-RAF", 
            "description": "Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors."
        }, 
        "biospec_descr": {
            "textblock": "Whole blood."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in\n      Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated\n      BRAF."
        }, 
        "brief_title": "Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "This is an observational prospective pilot study aimed to investigate the association\n      between changes of total and apoptotic CMC count and disease progression in MM patients\n      undergoing treatment with selective inhibitors of mutated B-RAF."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fourth stage Melanoma patients with both measurable and not measurable lesions\n             undergoing treatment with selective B-RAF inhibitors will be included. To determine\n             the prevalence of CMC-positive patients in IV stage Melanoma, patients without\n             mutated B-RAF undergoing chemotherapy and/or vaccines will be also enrolled at\n             baseline, as part of study protocols approved and activated in the participating\n             centers.\n\n          -  Informed written consent.\n\n        Exclusion Criteria:\n\n          -  Inadequate compliance to multiple blood draws (baseline, 15 days, 1th month, 4th\n             month, and/or at progression) as scheduled in this adjunctive biologic study for\n             patients carrying B-FAF mutation; inadequate compliance to adjunctive blood draws, as\n             scheduled at baseline for BRAF wild-type\n\n          -  Previously exposure to immunological treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878396", 
            "org_study_id": "IOV2011/35", 
            "secondary_id": "CE IOV 2011/35"
        }, 
        "intervention": {
            "arm_group_label": "Mutated Anti-B-RAF", 
            "intervention_name": "Anti-B-RAF", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Circulating Melanoma cells in metastatic melanoma", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "mgaliz@tiscali.it", 
                "last_name": "Vanna Chiarion-Sileni, MD", 
                "phone": "0039 0498215931"
            }, 
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "state": "PD", 
                    "zip": "35128"
                }, 
                "name": "Vanna Chiarion-Sileni, MD"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF", 
        "overall_contact": {
            "email": "mgaliz@tiscali.it", 
            "last_name": "Vanna Chiarion-Sileni, MD", 
            "phone": "0039 0498215931"
        }, 
        "overall_contact_backup": {
            "email": "rita.zamarchi@unipd.it", 
            "last_name": "Rita Zamarchi, MD", 
            "phone": "0039 0498215873"
        }, 
        "overall_official": {
            "affiliation": "Padua University", 
            "last_name": "Paola Zanovello, Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Italy: Ministry of Health", 
                "Italy: National Institute of Health", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of CMC count during treatment and comparison with CT and PET", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "reference": [
            {
                "PMID": "21206975", 
                "citation": "Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, Clack G, Malone M, Coumans FA, Terstappen LW. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011 Mar;38(3):755-60. doi: 10.3892/ijo.2011.896. Epub 2011 Jan 3."
            }, 
            {
                "PMID": "16899608", 
                "citation": "Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006 Aug 1;12(15):4605-13."
            }, 
            {
                "PMID": "20978147", 
                "citation": "Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010 Nov 1;16(21):5233-43. doi: 10.1158/1078-0432.CCR-10-1449. Epub 2010 Oct 26."
            }, 
            {
                "PMID": "22955853", 
                "citation": "Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer. 2012 Oct 9;107(8):1286-94. doi: 10.1038/bjc.2012.388. Epub 2012 Sep 6."
            }, 
            {
                "PMID": "15252844", 
                "citation": "Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004 Sep 20;111(5):741-5."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878396"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Istituto Oncologico Veneto IRCCS", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Diagnostics, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Istituto Oncologico Veneto IRCCS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}